At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 200 enrolled
Drug / intervention
Vi-CRM197 vaccine +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomized, Controlled, Observer Blind, Age De-Escalation, Multicenter and Multinational Study of the Safety, Reactogenicity and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants
In Brief
A Phase 2 clinical trial evaluating Vi-CRM197 vaccine, Vi Polysaccharide (PS) vaccine, and 1 other intervention for Typhoid Fever. Completed, enrolled 200 participants across 2 sites in 2 countries.
Detailed Summary
This phase 2 trial is aimed to obtain information on the safety and immunogenicity of the Vi-CRM197 in subjects from various age groups in India and Pakistan where Typhoid Fever is highly endemic and an efficacious vaccine against this disease is very much needed.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTyphoid Fever
CountriesIndia, Pakistan
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2010
Enrollment StartMar 2011
Primary CompletionJun 2012
TodayJul 2026
First PostedOct 27, 2010
Enrollment StartMar 1, 2011
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.7 years ago
Interventions
Vi-CRM197 vaccinebiological
Vi Polysaccharide (PS) vaccinebiological
Pneumococcal conjugate vaccinebiological